more

Novartis (NVS)

(Real Time Quote from BATS)

$114.15 USD

+0.20 (0.18%)

Updated Oct 7, 2024 01:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

Top 19% (47 out of 252)

Industry: Large Cap Pharmaceuticals

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Mesoblast (MESO) Up on Deal With BMT CTN to Develop GVHD Drug

by Zacks Equity Research Published on November 23,2023

Mesoblast (MESO) partners with Blood and Marrow Transplant Clinical Trials Network to develop a pivotal study on its lead candidate, Ryoncil, for acute graft versus host disease. The stock rises 11%.

The Zacks Analyst Blog Highlights Procter & Gamble, Novartis, Mondelez International, Elevance Health and Vertex Pharmaceuticals

by Zacks Equity Research Published on November 21,2023

Procter & Gamble, Novartis, Mondelez International, Elevance Health and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.

Top Stock Reports for Procter & Gamble, Novartis & Mondelez International

by Mark Vickery Published on November 20,2023

Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Novartis AG (NVS) and Mondelez International, Inc. (MDLZ).

Alnylam (ALNY) Swings to Earnings in Q3 on Collaboration Revenues

by Zacks Equity Research Published on November 03,2023

Alnylam (ALNY) reports better-than-expected third-quarter 2023 results, beating both earnings and sales estimates on the back of higher collaboration revenues.

Ionis (IONS) Q3 Loss Wider Than Expected, Sales Beat Estimates

by Zacks Equity Research Published on November 03,2023

Ionis (IONS) incurs a wider-than-expected third-quarter loss. Sales beat estimates. The company re-affirms its previously issued financial guidance for 2023.

pharmaceuticals

Incyte (INCY) Beats on Q3 Earnings, Misses Revenue Estimates

by Zacks Equity Research Published on October 31,2023

Incyte's (INCY) third-quarter 2023 earnings beat estimates, while revenues miss the same. The company tightens Jakafi net product revenue guidance for 2023.

Drug, Biotech Stocks' Q3 Earnings Due on Oct 31: AMGN, PFE, INCY

by Zacks Equity Research Published on October 30,2023

Let's take a look at three biotech/drug companies, AMGN, PFE and INCY, slated to release quarterly results on Oct 31.

Incyte (INCY) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research Published on October 27,2023

Higher sales of lead drug Jakafi and incremental sales of newly approved drugs are likely to have boosted Incyte's (INCY) top line during the third quarter of 2023.

biotechs

Pharma Stock Roundup: SNY, MRK, NVS Report Q3 Earnings, FDA Okays PFE, LLY Products

by Kinjel Shah Published on October 27,2023

Merck (MRK), Sanofi (SNY) and Novartis (NVS) report third-quarter results. FDA approves Pfizer's (PFE) Penbraya and Eli Lilly's (LLY) Omvoh

pharmaceuticals

Novartis (NVS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research Published on October 24,2023

The headline numbers for Novartis (NVS) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

NVSPositive Net Change

Novartis (NVS) Tops Q3 Earnings, Ups Operating Income View

by Zacks Equity Research Published on October 24,2023

Novartis (NVS) beats on earnings in the third quarter and raises its annual guidance for core operating income.

Novartis (NVS) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research Published on October 20,2023

Investor focus is likely to be on the top and bottom-line numbers, and updates on guidance post-Sandoz spin-off when Novartis (NVS) reports its third-quarter results.

Novartis (NVS) Stock Moves -0.4%: What You Should Know

by Zacks Equity Research Published on October 18,2023

Novartis (NVS) reachead $96.10 at the closing of the latest trading day, reflecting a -0.4% change compared to its last close.

NVSPositive Net Change

Aldeyra (ALDX) Plummets on Dry Eye Disease Drug's Setback

by Zacks Equity Research Published on October 17,2023

Aldeyra's (ALDX) new drug application for dry eye disease unlikely to be approved by the FDA due to its lack of efficacy.

Incyte (INCY) Stock Plummets 29.6% Year to Date: Here's Why

by Zacks Equity Research Published on October 13,2023

Incyte (INCY) loses 29.6% year-to-date as competition increases for Jakafi and the company suffers pipeline setbacks.

Novartis (NVS) Suffers a Larger Drop Than the General Market: Key Insights

by Zacks Equity Research Published on October 12,2023

The latest trading day saw Novartis (NVS) settling at $97.87, representing a -1.55% change from its previous close.

NVSPositive Net Change

Jasper (JSPR) Up on FDA Nod to Begin Early-Stage Urticaria Study

by Zacks Equity Research Published on October 10,2023

Jasper (JSPR) announces the FDA clearance to begin the clinical study of briquilimab for chronic spontaneous urticaria. The stock of the company rises 16%.

Bristol Myers (BMY) to Acquire Mirati Therapeutics for $5.8 B

by Zacks Equity Research Published on October 09,2023

Bristol Myers (BMY) to offset its declining revenues from top drugs with the acquisition of Mirati Therapeutics, which will add lung cancer drug Krazati to its portfolio.